Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | HBB | P68871 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | PNP | P00491 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | POLA1 | P09884 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13918113 | 1.00 | SLC29A1 (0.38) | SLC29A1CYP1A2HBBHIF1APNP | |
| SCHEMBL889578 | 0.92 | CYP1A2 (0.46) | SLC29A1CYP1A2HBBHIF1APNP | |
| SCHEMBL12570251 | 0.92 | CYP1A2 (0.46) | SLC29A1CYP1A2HBBHIF1APNP | |
| SCHEMBL12762714 | 0.89 | SLC29A1 (0.37) | SLC29A1CYP1A2HBBHIF1APNP | |
| SCHEMBL12570256 | 0.89 | SLC29A1 (0.37) | SLC29A1CYP1A2HBBHIF1APNP | |
| SCHEMBL888333 | 0.82 | CYP1A2 (0.41) | SLC29A1CYP1A2HBBHIF1APNP | |
| SCHEMBL890289 | 0.81 | SLC29A1 (0.44) | SLC29A1CYP1A2HBBHIF1A | |
| SCHEMBL12570170 | 0.81 | SLC29A1 (0.44) | SLC29A1CYP1A2HBBHIF1A | |
| SCHEMBL888198 | 0.81 | SLC29A1 (0.38) | SLC29A1CYP1A2HBBHIF1APNP | |
| SCHEMBL888335 | 0.80 | POLB (0.46) | CYP1A2HBBPNPPOLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110287427-A1 | 3'OH-UNBLOCKED, NUCLEOTIDES AND NUCLEOSIDES BASE MODIFIED WITH LABELS AND PHOTOCLEAVABLE, TERMINATING GROUPS AND METHODS FOR THEIR USE IN DNA SEQUENCING | LASERGEN, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20080132692-A1 | Photocleavable labeled nucleotides and nucleosides and methods for their use in DNA sequencing | AGILENT TECHNOLOGIES, INC. | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132692-A1 | Photocleavable labeled nucleotides and nucleosides and methods for their use in DNA sequencing | UNG, DCLRE1B, NT5C3B | SLC29A1 213/4885CYP1A2 4047/4885HBB 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.